Telix (TLX) and United Imaging Partner to Develop Theranostics; Shares Decline

Telix Pharmaceuticals (ASX: TLX) and Shanghai United Imaging Healthcare announced a partnership on June 2, 2026, to develop integrated theranostics workflows for precision oncology, sending Telix shares lower in afternoon trading. The collaboration aims to combine Telix’s radiopharmaceutical diagnostic and therapeutic agents with United Imaging’s advanced imaging systems to streamline cancer treatment protocols. Financial terms were not disclosed. The companies plan to explore solutions that unify molecular imaging and targeted radiotherapy, targeting improved patient outcomes. Telix shares fell on the Australian Securities Exchange following the announcement, though specific percentage declines were not immediately available. The partnership marks a further step in Telix’s expansion into theranostics, an emerging field that links diagnostics directly with therapy.